Indication

Metastatic renal cell carcinoma

Metastatic renal cell carcinoma is an advanced malignancy arising from the renal tubular epithelium that has disseminated beyond the kidney and Gerota’s fascia to distant anatomical sites. Read more about Metastatic renal cell carcinoma

19 drugs 19 manufacturers

Drugs that treat it

Common Metastatic renal cell carcinoma therapies.

Showing 19–19 of 19 drugs

Sort

YULITHIRA (everolimus)

ANTINEOPLASTIC - MTOR KINASE INHIBITORS·METASTATIC RENAL CELL CARCINOMA·+6

CIVICASCRIPT, L

Filter & compare in the drug finder →Opens the drug finder with Metastatic renal cell carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon

About Metastatic renal cell carcinoma.

Metastatic renal cell carcinoma is an advanced malignancy arising from the renal tubular epithelium that has disseminated beyond the kidney and Gerota’s fascia to distant anatomical sites.

Predominantly affecting adults and most commonly exhibiting clear cell histology, the disease spreads hematogenously and lymphatically, with frequent metastases to the lungs, bone, liver, brain, and distant lymph nodes.

Pathophysiologically, it is often driven by dysregulation of the von Hippel-Lindau pathway, leading to vascular endothelial growth factor accumulation, intense angiogenesis, and pronounced resistance to standard cytotoxic chemotherapy.

Clinically, it may manifest with localized symptoms such as flank pain and hematuria, site-specific metastatic complications, or systemic paraneoplastic phenomena including hypercalcemia and cachexia.

cancer.gov
Metastatic renal cell carcinoma is an advanced malignancy arising from the renal tubular epithelium that has disseminated beyond the kidney and Gerota’s fascia to distant anatomical sites Predominantly affecting adults and most commonly exhibiting clear cell histology, the disease spreads hematogenously and lymphatically, with frequent metastases to the lungs, bone, liver, brain, and distant lymph nodes
nih.gov
Metastatic renal cell carcinoma is an advanced malignancy arising from the renal tubular epithelium that has disseminated beyond the kidney and Gerota’s fascia to distant anatomical sites Predominantly affecting adults and most commonly exhibiting clear cell histology, the disease spreads hematogenously and lymphatically, with frequent metastases to the lungs, bone, liver, brain, and distant lymph nodes
nih.gov
Predominantly affecting adults and most commonly exhibiting clear cell histology, the disease spreads hematogenously and lymphatically, with frequent metastases to the lungs, bone, liver, brain, and distant lymph nodes Clinically, it may manifest with localized symptoms such as flank pain and hematuria, site-specific metastatic complications, or systemic paraneoplastic phenomena including hypercalcemia and cachexia
nih.gov
Pathophysiologically, it is often driven by dysregulation of the von Hippel-Lindau pathway, leading to vascular endothelial growth factor accumulation, intense angiogenesis, and pronounced resistance to standard cytotoxic chemotherapy
nih.gov
Pathophysiologically, it is often driven by dysregulation of the von Hippel-Lindau pathway, leading to vascular endothelial growth factor accumulation, intense angiogenesis, and pronounced resistance to standard cytotoxic chemotherapy
nih.gov
Clinically, it may manifest with localized symptoms such as flank pain and hematuria, site-specific metastatic complications, or systemic paraneoplastic phenomena including hypercalcemia and cachexia
cancer.gov
Clinically, it may manifest with localized symptoms such as flank pain and hematuria, site-specific metastatic complications, or systemic paraneoplastic phenomena including hypercalcemia and cachexia

Personalize your experience

Follow Metastatic renal cell carcinoma and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it